India: Preferred destination for outsourcing clinical trials

India: Preferred destination for outsourcing clinical trials
India has emerged as a desirable destination for outsourcing clinical trials. Shenaz Z Khaleeli, Technical Director, PharmaLeaf India, provides a regulatory perspective

The pharmaceutical contract services industry is faced with a decade of opportunity. While industry analysts recount the change in outsourcing strategies post the 2008 credit crunch in the first article, Waiting for the bounce back, the following two write ups, All ‘CRAM’ med up! and Playing BIG with CROs present a cross section of views from leading players themselves

Strategic partners in prosperity

Waiting for the bounce back
As global pharma continues to re-size, Indian CMOs and CROs are revamping their business models and moving to the next level, finds Viveka Roychowdhury

All ‘CRAM’ med up!
With an increase in the number of off-patent drugs available, the competition, both domestic and MNCs, are tapping custom manufacturing outsourcing in a big way. Usha Sharma provides an industry insight

Playing BIG with CROs
Slowly and steadily, the growing Indian CRO industry is expected to show positive growth in the coming future as well. Sachin Jagdale analyses the possible trends and challenges that the Indian CRO industry has to sail through